While single dose activated charcoal is effective in preventing drug absorption, repeated doses not only prevent absorption but also can increase systemic drug clearance. The mechanism for the latter effect may involve interruption of enterohepatic recycling and/or promotion of drug exsorption from the systemic circulation into the gut lumen. A comprehensive review of reported studies in volunteer subjects and overdose patients showed that repeated dose activated charcoal markedly decreased the half-life and/or increased the clearance of a wide range of drugs. Side-effects of the treatment were infrequent, but included aspiration pneumonia, diarrhoea and constipation. The addition of laxatives to repeated dose charcoal treatment did not offer any significant increase in drug clearance and is not recommended. It is suggested that the optimal regimen for the use ofrepeat dose activated charcoal in acute drug intoxications is an initial dose of75-100 g, followed by 50 g every 4 hours until the risks of systemic drug toxicity are reduced to an acceptable level.
treatment of drug overdoses. In addition, we have formulated recommendations for a standard treatment regimen for repeat-dose activated charcoal in acute intoxications.
Mechanism for enhancement of drug elimination by multiple doses of activated charcoal
The various routes by which drugs and their metabolites may enter the lumen of the gastrointestinal tract are summarised in Figure 1 . Single-dose activated charcoal is a well-established means of adsorbing many drugs and thus preventing their absorption into the blood stream. Multiple doses of charcoal can increase the amount of drug adsorbed where single dose drug binding is suboptimal because of poor binding characteristics of the drug, interference of food with binding or problems caused by the prolonged presence of sustained release drug products. The extent of biliary excretion of drugs and their conjugates is a reflection of the physicochemical characteristics of the drug. Enterohepatic recycling is interrupted by multiple doses of charcoal which trap drug and/or metabolites many hours after ingestion. Excretion in gastric juice or exsorption into the intestine is generally thought to be of minor importance. However, reabsorption in more distal parts of the gut may be responsible for this impression. While such excretion is small for some drugs (e.g. frusemide 9 ) it can be significant for others (e.g. theophyllinelO,ll). Passive diffusion of unbound (free) drug from the systemic circulation down a concentration or pH gradient into the gastrointestinallumen is the presumed mechanism for such transfer. Multiple doses of charcoal will provide maximum adsorption of suitable drug molecules, thus maintaining the concentration gradient and increasing systemic clearance. The effect should be greatest for drugs with medium to long half-lives.
Effects of multiple doses of activated charcoal on . drug elimination
Data showing the effect of multiple doses of activated charcoal on drug elimination have been summarised for both volunteer (Table 1) and patient (Table 2) studies.
The volunteer studies have used crossover designs where subjects were studied on two occasions (with and without charcoal). These studies have shown substa~ial increases in clearance (1.4 to 5.3 fold) and concomitant decreases in half-life for a wide variety of drugs (Table 1) . However, activated charcoal failed to increase elimination of chlorpropamide and imipramine. It should be noted that the results of these volunteer studies may overestimate the ability of activated charcoal to increase drug elimination since ethical considerations limit the drug dosage to therapeutic amounts, while usual doses of charcoal are still maintained. Studies of the efficacy of multiple-dose activated charcoal in patients have now been reported for several drugs (Table 2 ). For the most part, these were overdose situations and decreases in drug half-life ranged from 37 to 92%. In some cases, the investigators were able to obtain an estimate of drug half-life before starting therapy with charcoal and have compared this to the post-treatment halflife. In other studies, only post-treatment half-lives were obtained and these data can only be compared with other literature reports of drug half-life in overdose patients.
The effects of multiple-dose activated charcoal on the elimination of individual drugs are discussed in the following sections.
ANALGESICS AND ANTI-INFLAMMATORY DRUGS

Aspirin
In a study of five overdose patients, multiple doses of activated charcoal reduced salicylate halflife from a mean of 27 to 3.2 hours. 29 Recently, a study in thirteen volunteer subjects 13 has shown that three doses of activated charcoal were superior to either one or two doses in preventing aspirin absorption and/or increasing its non-renal clearance ( Figure 2 ). 
Carbamazepine
This commonly encountered anticonvulsant has only been studied in volunteers l4 where oral clearance was increased by 82% using a total of 118 g charcoal.
Phenytoin
There is only one recorded case of repeat dose activated charcoal use for phenytoin overdose. 4o Peak serum phenytoin levels of 52 mg/l were reduced to 7 that for phenytoin in normal subjects (0.25 to 1 day47) and thus the efficacy of repeat dose activated charcoal is questionable until further studies are available.
Phenobarbitone
The effects of repeated charcoal on phenobarbitone elimination have been studied in both volunteers and patients. An extensive study37 in overdosed patients showed a reduction in mean half-life from 93 to 36 hours. Other patient studies3o.38.39 have reported even shorter half-lives for phenobarbitone (3.4 to 24 hours) after activated charcoal. A larger dose of charcoal may be a factor in the apparently greater reduction in phenobarbitone half-life in the latter studies. ANTIDEPRESSANTS This group of drugs accounted for 19.7% of all poisons in a recent survey of overdose cases in Australia. 48 
Amitriptyline
Studies in v olunteers 1 2 who received a 75 mg oral dose of amitriptyline showed 20% and 35% decreases in the half-lives of amitriptyline and nortriptyline respectively. The greater efficacy of charcoal in the elimination of nortriptyline was suggested to be due to its greater degree of enterohepatic and enterogastric recirculation.
Doxepin
Neither the half-life of doxepin nor the clearance in volunteer subjects was significantly altered by repeated doses of activated charcoal. 2o However, the clearance of desmethyldoxepin was significantly greater (x 1.6) than that achieved after a single dose of activated charcoal or in control subjects. The doses of doxepin (50 mg) and charcoal (55 gl24 hr) were both small and considered together with the fact that doxepin has ~ fairly large volume of distribution (20 litreslkg) and is extensively demethylated,47 may account for the lack of a significant increase in clearance of the parent drug.
Imipramine
. Results in volunteers who were given a small ~nt~aven~)Us therapeutic dose (180 Ilglkg) of Imlpranune 21 showed little or no effect of repeated doses of activated charcoal on drug half-life or clearance. Again, the large volume of distribution for this drug (15litreslkg 47 ) would mitigate against an increased drug clearance at the low dose levels which are possible in volunteer studies.
CARDIAC GLYCOSIDES AND ANTIARRHYTHMICS
Digoxin and Digitoxin
Following intravenous dosage in volunteers, clearances of both digoxin I8 ,19,34 and digitoxin 19 were increased between 35 and 95%. These impressive findings were confirmed in patients where the half-lives were reduced from 93.3 to 29.3 hours and from 175 to 33.6 hours for digoxin l9 ,34 and from 162 to 18 hours for digitoxin. 35 
Quinine
Recent studies in both volunteers 24 and overdose p~ti~nts~1 show ~ marked increase in drug ehmmatlon followmg multiple doses of activated charcoal. Oral plasma clearance in volunteers 24 was increased by 56% while in five overdose patients 41 mean half-life was 8.1 hours which w~s considerably shorter than the 24-hour mean reported in poisoned patients. 49
BETA-ADRENOCEPTOR ANTAGONISTS
Nadolol
The half-life of this antihypertensive agent has been shown to be reduced from a mean of 17.3 to 11.8 hours in volunteer studies. 22 It is interesting to note that the authors of this study used doses of a.ctivated charcoal ranging from approximately 3-6 tImes that of the therapeutic dose (80 mg) of nadolol given to their subjects. By contrast, all of the other volunteer studies in Table 1 have used activ.ated c~arcoal i~ ~epeated doses of 20-50 g despIte havmg admlmstered normal therapeutic doses of a variety of drugs.
Sotalol
The half-life ofthe drug was significantly reduced by 19% in a volunteer study.25
OTHER DRUGS
Chlorpropamide
A study in six volunteers failed to show any alteration in chlorpropamide disposition despite adequate repeated doses of charcoal. 15 Cyciosporin
The only study is that of Honcharik et al., 31 in which a renal transplant patient was given cyclosporin 5 g in error. Repeat-dose activated charcoal resulted in a 70% decrease in half-life.
Dapsone
Methaemoglobinemia and haemolytic anaemia are the principal complications following overdose with this anti-leprotic agent. The results of both a well-conducted volunteer study16 and five separate overdose patient studies l6 ,32 indicate that repeat dose charcoal is highly effective in decreasing dapsone half-life. In the volunteer study, a 50% reduction was achieved while in the patient studies reductions ranged from 65 to 85%.
Meprobamate
In ~ study in two patients, 36 Hassan reported half-bves of 4.4 and 4.5 hours respectively following repeated activated charcoal. These halflives can be compared to a mean of 11.3 hours in volunteer subjects, 50 and indicate that the treatment is effective. Theophylline This is possibly the best documented drug showing altered disposition following multiple doses of activated charcoal. In volunteers given therapeutic doses of the drug, repeated charcoal doubled clearance 27 and/or decreased half-life by 48_69%. [26] [27] [28] In overdose patients 27 ,28,30,40,42-46 initial half-lives (mean 24.1 hr, range 16.2-34.4 hr) were markedly reduced (mean 6.7 hr, range 2-13.9 hr). A typical patient study is shown in Figure 3 . The considerably longer initial half-lives in the patient group reflect the non-linear disposition of this drug which is most likely to be seen at high plasma concentrations. 51 Vomiting may also occur as a direct result of theophylline toxicity52 and can severely limit the use of activated charcaol. 53, 54 Continuous nasogastric infusion of charcoal (30-50 glhr) may be a preferred alternative in the presence of vomiting. 46 In the event of persistent vomiting from high theophylline levels our own experience suggests that endotracheal intubation and controlled ventilation followed by repeated charcoal is an effective alternative to charcoal haemoperfusion. Multiple dose charcoal has been recommended also for theophylline poisoning in young infants.44
ROLE OF MULTIPLE DOSE ACTIVATED CHARCOAL IN MINIMISING DESORPTION OF DRUGS OR POISONS
The reversibility and stability of the binding of drugs and poisons to activated charcoal has been reviewed previously.55,8 While desorption during passage through the intestinal tract has been demonstrated, it is not thought to be clinically significant. Multiple doses of charcoal would be expected to minimise such desorption since they generally increase drug removal.
SIDE-EFFECTS ASSOCIATED WITH ACTIVATED CHARCOAL
Orally administerd activated charcoal per se is non-toxic 56 and its use at doses of 20-50 glday for 4 to 20 months in treatment of uremia was not associated with any significant side-effects. 57 The texture and taste of charcoal suspensions makes them unpleasant to swallow and thus oral charcoal can sometimes induce vomiting. Pneumonitis and other complications have been reported after aspiration of charcoal and gastric contents. 58-60 Such problems are less likely when the trachea is intubated and multiple-dose charcoal is administered through a nasogastric tube. Charcoal is also reported to be a cause of constipation, intestinal obstruction and diarrhoea. Constipation is a common side-effect of charcoal therapy55,61 and may be treated readily with sorbitol (already contained in some activated charcoal preparations), lactulose or liquid paraffin. Intestinal obstruction has been reported in two patients given large doses (240 or 300 g) of charcoal,62,63 while a charcoal bezoar formed in the small intestine of another patient who had taken an amitriptyline overdose and was given charcoal. 64 On the other hand, diarrhoea has resulted from use of a charcoal preparation containing Anaesthesia and Intl!7lSive Care, Vol. 18, No. 3, August, 1990 polyvinylpyrollidine as a suspending agent. 41 Repeated administration of charcoal preparations containing large amounts of sorbitol or sodium bicarbonate should be undertaken cautiously as these additives may cause hypotension and electrolyte disturbances. 65 ,66 It should also be remembered that charcoal may prevent absorption and/or increase systemic clearance of a wide variety of orally or parenterally administered drugs which might need to be given in the treatment of overdose.
EFFECTS OF LAXATIVES AND PURGATIVES ON THE EFFICACY OF ACTIVATED CHARCOAL
The combination of multiple doses of activated charcoal and laxatives/purgatives may be expected to increase the elimination of drugs or poisons from the gastrointestinal tract by minimising the time available for desorption. Based on plasma levels, area under the plasma concentration-time curve and a decreased intestinal transit time, sorbitol has been shown to increase the efficacy of repeated doses of activated charcoal in the elimination of theophylline. 66 However, for phenobarbitone, sorbitol plus charcoal was only slightly better than charcoal alone,67 while other studies have failed to show increased elimination for aspirin 68 or paracetamol. 69 In addition, neither oral magnesium citrate nor a purgative mixture of rectal bisacodyl and metoclopramide increased the effects of charcoal on elimination of aspirin, atenolol or phenylpropanolamine,70 while purgatives such as sodium sulphate and magnesium citrate were ineffective in increasing activated charcoal elimination of aspirin 71 ,72 or paracetamol. 73 Thus, the efficacy of such combinations is controversial.
Disadvantages of the use of laxatives are abdominal cramping, diarrhoea and dehydration with loss of electrolytes. 69 However, there may be a case for including a laxative such as sorbitol with the initial dose of charcoal so that the decreased intestinal motility which occurs after some intoxications (e.g. anti-muscarinic drugs) is minimised.
RECOMMENDATIONS FOR MULTIPLE DOSE ACTIVATED CHARCOAL USE IN ACUTE INTOXICA TIONS
In formulating dose recommendations for charcoal, we have considered only the data in Table  2 , since they represent real overdose situations. Initial dose size varied from 20-150 g while repeat doses varying from 17-90 g were given at frequencies ranging from 4 to 8 hours. Since treatment in these studies was by and large efficaceous, we suggest that the initial dose size for adults should be 75-100 g and that repeat doses of 50 g should be administered every four hours until the risks of adverse effects are at an acceptable level. The large initial dose is desirable on the basis that at early times, there may be other substances in the gastrointestinallumen which could decrease the number of charcoal binding sites available for drug adsorption. Where reduced gastrointestinal motility is a feature of the poisoning, the osmotic laxative sorbitol (50-100 g)74.75 coUld be added to the initial charcoal dose.
For paediatric patients a continuous charcoal infusion of 0.25-0.5 gm/kg/hr (up to 50 gm/hr) is effective and may result in a lower incidence of vomiting than the use of intermittent bolus doses. 46 We conclude that repeated dose activated charcoal is a satisfactory alternative to charcoal haemoperfusion or haemodialysis in the treatment of overdoses of phenobarbitone,39 theophylline 42 and dapsone,55 and may be better treatment for overdoses of quinine 41 and tricyclic antidepressants. 55 ACTIVATED CHARCOAL PREPARATIONS AVAILABLE IN AUSTRALIA Activated charcoal of a suitable grade can be obtained in bulk from a variety of pharmaceutical wholesalers and should be mixed with water in a ratio of about 1:4 to form a slurry which is suitable for oral ingestion or nasogastric administration. There appear to be only two ready-made preparations which are packaged specifically for use in emergency toxicology. These are Carbosorb* (Delta West Ltd) containing Activated Charcoal BPC 50 g suspended in sterile purified water 300 ml and Carbosorb SR (Delta West Ltd) containing Activated Charcoal BPC 50 g, 70% Sorbitol Solution BP 150 ml and sterile purified water to a total volume of 300 ml. Both are packaged in a PVC bag with a twist-off nozzle which enables direct connection to an orogastric tube.
